Imagine printing a 3D object, but instead of adding layers of plastic one by one, you use a sheet of light to instantly freeze a gel full of living cells into a complex shape. It's like taking a 3D snapshot that turns liquid into solid tissue almost instantly. This allows for much faster creation of realistic body parts like skin or corneas without damaging the cells.
Current 3D bioprinting is too slow and lacks the resolution to mimic the complex, heterogeneous nature of real human tissues. This limits its use in drug testing and clinical therapies.
Two prototype bioprinters and a reproducible bioink. They also developed bioengineered models of skin, cornea, and gut tissue.
If you are a drug discovery lab dealing with inaccurate animal testing results — this project developed a light-sheet bioprinting technology that creates complex gut and skin tissue models. This allows for more accurate human-like testing of new medicines.
If you are a cell therapy clinic dealing with the inability to create complex 3D organ structures — this project developed a top-down lithography approach that produces high-resolution engineered tissues. This enables the creation of functional cornea and skin grafts for patients.
If you are a hardware manufacturer dealing with slow printing speeds and low resolution in 3D bioprinters — this project developed two prototype bioprinters using digital light-sheet illumination. This increases production speed while maintaining high cell viability.
Based on available project data, specific pricing is not mentioned, but the project aimed to produce a cost-effective bioink and a valid business case for a commercial product.
The project concluded with a 'go' decision for the industrialization of a bioprinting product and the establishment of the Modulux3D entity to move forward commercially.
Based on available project data, the project involved a consortium of 5 partners and resulted in a commercial path forward via the Modulux3D entity, though specific licensing terms are not listed.
The project focused on an ultra high-speed digital light-sheet strategy to overcome the insufficient speed of current layer-by-layer methods, though specific time-per-print numbers are not provided.
The technology provides a top-down lithography approach to create tissues like skin, cornea, and gut, which can be integrated into drug testing and toxicology workflows.
The consortium is lean and commercially oriented, consisting of 5 partners across 4 countries. With an industry ratio of 40% (including 2 industry partners and 1 SME), the group balances academic research from 2 universities with a clear drive toward market entry, evidenced by the transition from research to the Modulux3D commercial entity.
Contact MYCRONIC AB in Sweden for commercial inquiries regarding Modulux3D.
Contact us to explore licensing opportunities for light-sheet bioprinting technology.
